The purpose of this study is to register the follow-up data of patients who, because of a peritoneal surface malignancy, will undergo cytoreductive surgery and HIPEC.
|First Received Date||June 8, 2012|
|Last Changed Date||October 15, 2018|
|Start Date||May 2012|
|Anticipated Primary Completion Date||January 2025|
|Primary Outcome Measures||
To improve the prognosis/survival of patients with malignancies localized on the peritoneal surface. [Time Frame: Follow-up over a time period of at least 5 years]
|Study Arms / Comparison Groups||0 / 1|
To register the follow-up data of patients who, because of a peritoneal surface malignancy, will undergo cytoreductive surgery and HIPEC. In this surgical intervention, the abdominal cavity is macroscopically cleared of tumor, by removing all visible tumor nodules, and is subsequently rinsed with hyperthermic (heated) chemotherapy, aiming to destroy all residual invisible tumor cells that might have stayed behind after the debulking.
The eventual aim of this procedure is to improve the prognosis/survival of patients with malignancies localized on the peritoneal surface.
|Ages||N/A - N/A|
|Accepts Healthy Volunteers||No|
Isabelle B Terrasson
Phone: +32 16 340837
- Patients with peritoneal carcinomatosis of colorectal origin, patients with pseudomyxoma peritonei (type DPAM or PMCA) and patients with peritoneal mesothelioma who are planned to undergo cytoreductive surgery and HIPEC because of a peritoneal surface malignancy
|Sponsor||Universitaire Ziekenhuizen Leuven|
|Verification Date||October 2018|